TriangleFOR PATIENTS · SOURCE READING
Targeted therapy
Source: Thymoma and Thymic Carcinoma, National Cancer Institute.
Source updated: January 11, 2023 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: Thymoma and thymic carcinoma treatment
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors are types of targeted therapies used in the treatment of thymoma and thymic carcinoma.
Source links and citations
TKIs: This treatment blocks signals needed for tumors to grow. Sunitinib and lenvatinib are TKIs that may be used to treat recurrent thymoma or recurrent thymic carcinoma.
Source links and citations
mTOR inhibitors: This treatment blocks a protein called mTOR, which may keep cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. Everolimus is an mTOR inhibitor that may be used to treat recurrent thymoma or recurrent thymic carcinoma.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice